Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study

Abstract: An extrafine formulation of the long-acting muscarinic antagonist glycopyrronium bromide (GB) is in development for chronic obstructive pulmonary disease (COPD), in combination with beclometasone dipropionate and formoterol fumarate—a “fixed triple”. This two-part study was randomized, double blind, placebo controlled in patients with moderate-to-severe COPD: Part 1: single-dose escalation, GB 12.5, 25, 50, 100 or 200 µg versus placebo; Part 2: repeat-dose (7-day), four-period crossover, GB 12.5, 25 or 50 µg twice daily (BID) versus placebo, with an open-label extension in which all patients received tiotropium 18 µg once daily. On the morning of Day 8 in all five periods, patients also received formoterol 12 µg. In study Part 1, 27 patients were recruited. All GB doses significantly increased from baseline forced expiratory volume in 1 second (FEV₁) area under the curve (AUC₀–₁₂h) and peak FEV₁, with a trend toward greater efficacy with higher GB dose. All adverse events were mild–moderate in severity, with a lower incidence with GB than placebo and no evidence of a dose–response relationship. In study Part 2, of 38 patients recruited, 34 completed the study. Adjusted mean differences from placebo in 12 h trough FEV₁ on Day 7 (primary) were 115, 142 and 136 mL for GB 12.5, 25 and 50 µg BID, respectively (all P<0.001). GB 25 and 50 µg BID were superior (P<0.05) to GB 12.5 µg BID for pre-dose morning FEV₁ on Day 8. For this endpoint, GB 25 and 50 µg BID were also superior to tiotropium. Compared with Day 7, addition of formoterol significantly increased Day 8 FEV₁ peak and AUC₀–₁₂h with all GB doses and placebo (all P<0.001). All adverse events were mild–moderate in severity and there was no indication of a dose-related relationship. This study provides initial evidence on bronchodilation, safety and pharmacokinetics of extrafine GB BID. Overall, the results suggest that GB 25 µg BID is the optimal dose in patients with COPD.

Keywords: glycopyrronium, COPD, bronchodilator, dose-ranging

Introduction

Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation, with long-acting bronchodilators (muscarinic antagonists [LAMAs] or β₂-agonists [LABAs]) central to maintenance treatment, either alone or in combination.¹ LAMAs such as tiotropium have demonstrated efficacy in a range of measures, including lung function, exacerbations, dyspnea and health status.²⁻⁷ “Open” triple therapy, consisting of a LAMA in one inhaler and an inhaled corticosteroid (ICS) plus a LABA in a second, is often used in clinical practice, and is recommended as a treatment option for patients who have the highest level of symptoms and risk of future exacerbations.¹ Clinical trials have shown a benefit for the addition of a LAMA to an ICS/LABA; in particular, the addition of the LAMA glycopyrronium to a LABA/ICS significantly improved lung function, health status and rescue medication use.⁸
An extrafine formulation of glycopyrronium bromide (GB) is in development for management of COPD, to be used in a pressurized metered dose inhaler (pMDI) in combination with the ICS beclometasone dipropionate (BDP) and the LABA formoterol fumarate (FF) – a “fixed triple”. This combination has demonstrated improvements in lung function and exacerbation rates compared with BDP/FF\(^3\) and compared with tiotropium.\(^4\) The Phase II study described here was conducted as part of the development program of the BDP/FF/GB fixed triple. The overall aim of the study was to assess the bronchodilator efficacy of extrafine GB, to identify the optimal dose to be subsequently combined with BDP/FF. In addition, the effects of GB were compared to those of LAMA, tiotropium, and the additive bronchodilator effect of using formoterol with GB was also evaluated.

**Methods**

**Participants**

The study recruited males and females, 40–75 years of age, with moderate to severe COPD, specifically with post-bronchodilator forced expiratory volume in 1 second (FEV\(_1\)) 40%–80% predicted and FEV\(_1\)/forced vital capacity (FVC) ≤0.70. Eligible patients had reversibility ≥100 mL within 30–45 min after inhalation of ipratropium 80 µg and were current or ex-smokers with a smoking history of ≥10 pack-years. Exclusion criteria included: other significant lung diseases (such as asthma); a history of chronic or seasonal allergy; blood eosinophils >0.6×10\(^9\)/L; clinically relevant findings on physical examination or from laboratory or electrocardiogram (ECG) evaluations; or a respiratory tract infection 4 weeks prior to examination or from laboratory or ECG abnormalities at screening (described in the Supplementary materials). All patients signed written informed consent for the study, and the study was approved by the local research ethics committee (North West – Greater Manchester Central, UK; Ref: 10/H1008/47). All the inclusion and exclusion criteria are given in the Supplementary materials. Patients who completed study Part 1 were eligible for study Part 2, provided they still met the inclusion and exclusion criteria.

**Trial design**

The two-part study was randomized, double blind and placebo controlled (ClinicalTrials.gov registration: NCT01176903). Part 1 was a two-cohort, single-dose escalation design, with the dose escalated only if the safety and tolerability profile of the lower dose was acceptable. Cohort A was randomized to receive GB 12.5, 50 or 200 µg, via pMDI, or matching placebo; there were three treatment periods separated by washouts of ≥7 days. Cohort B was randomized to receive GB 25 or 100 µg or placebo in two treatment periods. Treatment sequences were defined to ensure a 10:2 ratio between GB and placebo in each period.

Part 2, which started only after a positive evaluation of safety data from Part 1, was repeat-dose, four-period cross-over design, followed by an open-label extension period. In the first four (core) periods, patients were randomized to receive GB 12.5, 25 or 50 µg, or matching placebo, twice daily (BID) for 7 days (total daily doses of 25, 50 and 100 µg), with a further dose on the morning of Day 8. In the fifth (extension) period, all patients received tiotropium 18 µg once daily (OD) for 8 days, open-label via the manufacturer’s single-dose dry powder inhaler. On the morning of Day 8 in all five treatment periods, patients also received a single dose of formoterol 12 µg via pMDI. Treatment periods were separated by a 7±2 day washout.

Patients were assigned to treatment sequences according to randomization lists prepared by the study sponsor. Patients, investigators and site staff, monitors, and the sponsor’s clinical team were all blinded to GB and placebo treatment.

**Visit schedule**

After completing the screening visit, eligible patients entered a 7-day run-in, when LAMAs and LABAs were discontinued; LAMAs were replaced with ipratropium four times a day (withheld from 24 h before each study visit until the end of the treatment period) and LABAs were replaced with salbutamol as needed (prn). All patients were permitted salbutamol prn during the treatment periods, with a 6 h washout prior to any pulmonary function test. ICS use was permitted throughout the study, provided the dose had been stable for ≥4 weeks prior to entry (patients taking ICS/LABA fixed combination were prescribed ICS at an equivalent dose plus salbutamol prn).

In study Part 1, lung function was assessed pre-dose, and 15, 30 and 45 min and 1, 2, 4, 6, 8, 10, 12, 12.5 and 24 h post-dose. In study Part 2, lung function was assessed pre-dose on Day 1, and pre-dose and 15, 30 and 45 min and 1, 2, 4, 6, 8, 10 and 12 h post-dose on days 7 and 8. Blood samples were collected for pharmacokinetic (PK) analysis on days 1 and 7 of study Part 2 at pre-dose and at 5, 10, 15 and 30 min and 1, 2, 4, 6, 8 and 12 h post-dose, and pre-dose on Day 6. Urine samples were collected pre-dose on Day 1, and at 0–4 h and 4–12 h on days 1 and 7.
Objectives and outcomes

Study Part 1
The primary objective was to assess the safety and tolerability of single-dose GB at five dose levels. Secondary objectives were to assess the bronchodilator effects of GB, compared with placebo, in terms of FEV₁ area under the curve from 0 to 12 h (AUC₀₋₁₂h) normalized by time, and peak FEV₁.

Study Part 2
The primary objective was to assess the bronchodilator efficacy of GB compared to placebo, in terms of 12 h trough FEV₁ on Day 7 (using data collected at 12 h after morning administration of medication on Day 7).

Secondary objectives included: evaluation of the bronchodilator effects of GB versus placebo on Day 7, in terms of FEV₁, AUC₀₋₁₂h, normalized by time, and peak FEV₁, and comparison of GB with placebo and tiotropium, with respect to pre-dose morning FEV₁ on Day 8. Safety and tolerability was assessed by adverse events (AEs), ECGs (12-lead and 24 h Holter), vital signs and laboratory tests. The PK profile of GB was analyzed after single (on Day 1) and repeated administration (ie, at steady state, assessed on Day 7).

An exploratory objective was to evaluate the additive effect of single-dose formoterol over GB; the difference between 8 and 7 days (ie, with and without formoterol) in peak FEV₁, FEV₁, AUC₀₋₁₂h, normalized by time and 12 h trough FEV₁ was determined.

Sample size
There was no formal power calculation for study Part 1, as this was primarily performed for safety evaluation. A sample size of 24 patients (12 patients per cohort: 10 on GB and 2 on placebo in each treatment period) was considered sufficient for dose escalation. Dropouts were replaced to have at least 11 evaluable patients per cohort.

For the primary endpoint of study Part 2 (12 h trough FEV₁ on Day 7), 32 evaluable patients provided 80% power to detect a mean difference of 120 mL between at least one dose of GB and placebo at a two-sided significance level of 0.05, adjusting for multiplicity using Hommel's method and assuming a within-subject standard deviation (SD) of 140 mL. Assuming a nonevaluable rate of 20%, a total of 40 patients would need to be randomized. Patients prematurely withdrawing were not replaced.

Statistical methods
In study Part 1, FEV₁, AUC₀₋₁₂h (normalized by time) and peak FEV₁ were analyzed descriptively, and the mean change from baseline and 95% confidence intervals are presented. In study Part 2, trough FEV₁ at 12 h post-dose on Day 7 was analyzed using an analysis of covariance (ANCOVA) model (core periods only), with treatment, period and patient as fixed effects and baseline FEV₁ (pre-dose on Day 1) as the covariate. The P-values of the comparisons between each dose of GB and placebo were adjusted for multiplicity using Hommel's method. FEV₁, AUC₀₋₁₂h (normalized by time) and peak FEV₁ on Day 7 were analyzed using the same ANCOVA model as for the primary variable, but without adjustment for multiplicity. Pre-dose morning FEV₁ on Day 8 was submitted to an ANCOVA model with treatment and patient as fixed effects and baseline FEV₁ as the covariate. For the exploratory objective, data on Day 8 (ie, after administration of formoterol) were compared with the respective values on Day 7 using paired t-tests. PK parameters were calculated using standard noncompartmental methods.

AEs, serious AEs (SAEs) and AEs leading to study withdrawal were presented descriptively; absolute values and mean changes from baseline were calculated for other safety parameters, with abnormal findings summarized by treatment. In both parts of the study, all randomized patients were included in the efficacy, safety and PK analyses.

Results

Participants
In study Part 1, 66 patients were screened, and 27 were recruited (23 were initially randomized; 4 prematurely withdrew and were replaced), as shown in Figure 1A. In study Part 2, 145 patients were screened and 38 were randomized, with 34 completing it (Figure 1B). Baseline demographics and disease characteristics of the randomized patients are shown in Table 1.

Efficacy

Study Part 1
All GB doses were associated with statistically significant increases from baseline in FEV₁ AUC₀₋₁₂h (Figure 2) and peak FEV₁ (Figure 3). The largest differences compared to placebo were observed with the three highest GB doses (50, 100 and 200 µg); both the FEV₁ AUC₀₋₁₂h and peak FEV₁ data suggest the plateau of the dose response curve had been reached at these doses.

Study Part 2
Primary endpoint
All three GB doses resulted in statistically significant increases versus placebo in terms of 12 h trough FEV₁ on
Figure 1A Patient flow through Part 1 of the study.
Notes: *Including four replacement patients. †Patients were replaced, with replacements starting from the next treatment planned to be administered to the withdrawn patients, such that there were 12 evaluable patients in each treatment period.
Abbreviation: ECG, electrocardiogram.

Figure 1B Patient flow through Part 2 of the study.
Note: *Reasons included spirometry results, poor venous access and recruitment having been stopped.
Day 7, with no significant differences between GB doses (Figure 4). The adjusted mean (95% confidence interval) differences compared to placebo were 115 (76, 155), 142 (102, 182) and 136 (96, 176) mL for the 12.5, 25 and 50 µg BID doses, respectively.

Secondary endpoints
All three GB doses were associated with statistically significant improvements versus placebo in terms of FEV$_1$AUC$_{0–12h}$ normalized by time on Day 7, with no significant difference between GB doses (Figure 5). Mean changes from baseline in peak FEV$_1$ values on Day 7 were 292, 320 and 332 mL for GB 12.5, 25 and 50 µg BID, respectively, compared with 83 mL for placebo ($P<0.001$ for all GB doses versus placebo). The difference between GB 12.5 and 25 µg BID was significant ($P=0.034$).

Comparisons with tiotropium
For pre-dose morning FEV$_1$ on Day 8, all three GB doses were associated with statistically significant increases versus placebo, with the two highest GB doses being statistically superior to both tiotropium and GB 12.5 µg BID (Figure 6). The adjusted mean differences versus tiotropium were 71 and 47 mL with GB 25 and 50 µg BID, respectively.

Add-on formoterol
Compared with the Day 7 data, the addition of formoterol resulted in statistically significant increases in Day 8 peak

---

**Table 1** Patient baseline demographics and disease characteristics

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Study Part 1 (n=27)</th>
<th>Study Part 2 (n=38)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male gender, n (%)</td>
<td>7 (26)</td>
<td>15 (39)</td>
</tr>
<tr>
<td>Race, caucasian, n (%)</td>
<td>27 (100)</td>
<td>37 (97)</td>
</tr>
<tr>
<td>Age, years, mean (range)</td>
<td>57.5 (42–72)</td>
<td>56.8 (42–73)</td>
</tr>
<tr>
<td>Smoking status, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ex-smoker</td>
<td>16 (59)</td>
<td>17 (45)</td>
</tr>
<tr>
<td>Smoker</td>
<td>11 (41)</td>
<td>21 (55)</td>
</tr>
<tr>
<td>Pack-years, mean (range)</td>
<td>36.6 (20.0–52.3)</td>
<td>36.3 (15.0–93.0)</td>
</tr>
<tr>
<td>Duration of smoking, mean (range)</td>
<td>38.3 (13.6–54.6)</td>
<td>39.4 (24.0–54.0)</td>
</tr>
</tbody>
</table>

Note: *Post-bronchodilator.

Abbreviations: FEV$_1$, forced expiratory volume in 1 second; FVC, forced vital capacity.
(Figure 7), FEV\textsubscript{1} AUC\textsubscript{0–12h} (Figure 8) and 12 h trough FEV\textsubscript{1} (Figure S1) with all treatments. The magnitude of increase caused by formoterol added to placebo was approximately double that of formoterol added to GB; for example, for FEV\textsubscript{1} AUC\textsubscript{0–12h} the increases were ~200 and 100 mL, respectively.

**Safety and tolerability**

**Study Part 1**

All of the AEs during study Part 1 were mild or moderate in severity, with a lower incidence with GB than placebo and no evidence of a dose-related trend (Table 2). Mean changes over time in the ECG parameters were similar following all treatments (including placebo). No patient had a Fridericia’s corrected QTc (QTcF) interval value above 480 ms or a change from baseline of more than 60 ms. Two patients withdrew due to AEs – atrial fibrillation in a patient receiving placebo and ventricular extrasystoles in a patient receiving GB 50 µg. Two more patients withdrew due to ECG findings – one with a first-degree atrioventricular block.
following 12.5 µg GB and with a QTc value above normal at screening (the patient had completed the first treatment period by the time the decision was taken to withdraw the patient, and therefore was included in the analyses).

Study Part 2
There was no dose-related trend in AE incidence. All AEs were mild or moderate in severity, with no deaths or SAEs (Table 3). Few changes in laboratory parameters were observed, with no relevant differences in treatment-emergent laboratory abnormalities between any GB dose, tiotropium or placebo. Mean changes over time in all ECG parameters were similar over time for all treatments. No patient had a QTcF interval value above 480 ms; one patient had a change from baseline in QTcF interval >60 ms (during treatment with GB 50 µg BID).

PK (Study Part 2)
Pre-dose mean plasma GB concentrations were similar on days 6 and 7, indicating that plasma steady state was reached within 6 days. GB plasma and urine PK parameters on days 1 and 7 are shown in Table 4. At a steady state, the mean maximum plasma concentration (C_{max,ss}) increased proportionally with dose, as did systemic exposure over the first 30 min post-dose (AUC_{0-30,min,ss}). Systemic exposure assessed by both AUC_{0-12h,ss} and AUC_{0-144h} increased more than proportionally across the full dose range, but approximately proportionally between 25 and 50 µg BID. In contrast, although the plasma elimination half-life (t_{1/2,el}) increased from 12.5 to 25 µg BID, the values were similar with the two higher doses. The median accumulation ratio (R_{ac}) was also similar across doses (note that due to high variability of R_{ac} values with the 25 and 50 µg doses, the median is more reliable than the mean). Mean urinary GB excretion increased proportionally with dose; in contrast, renal clearance decreased slightly with increasing dose.

Discussion
The dose ranging study reported here provides information on bronchodilation, safety and PK of single and multiple

<table>
<thead>
<tr>
<th>Table 2 Study Part 1: Overall experience of AEs and SAEs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo (n=10)</td>
</tr>
<tr>
<td>Any treatment-emergent AE, n (%)</td>
</tr>
<tr>
<td>Most frequently reported treatment-emergent AE (≥2 patients with any treatment)*</td>
</tr>
<tr>
<td>Headache, n (%)</td>
</tr>
<tr>
<td>Oropharyngeal pain, n (%)</td>
</tr>
<tr>
<td>Constipation, n (%)</td>
</tr>
<tr>
<td>AEs considered treatment related by the investigator, n (%)</td>
</tr>
<tr>
<td>AE leading to study withdrawal, n (%)</td>
</tr>
<tr>
<td>SAEs, n (%)</td>
</tr>
</tbody>
</table>

Note: *Sorted by frequency in GB treatments.
Abbreviations: AE, adverse event; GB, glycopyrronium bromide; n, number of randomized patients; SAE, serious adverse event.

<table>
<thead>
<tr>
<th>Table 3 Study Part 2: Overall experience of AEs and SAEs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo (n=35)</td>
</tr>
<tr>
<td>Any treatment-emergent AE, n (%)</td>
</tr>
<tr>
<td>Most frequently reported treatment-emergent AEs (≥2 patients with any treatment)*</td>
</tr>
<tr>
<td>Headache, n (%)</td>
</tr>
<tr>
<td>Back pain, n (%)</td>
</tr>
<tr>
<td>Cough, n (%)</td>
</tr>
<tr>
<td>AEs considered treatment related by the investigator, n (%)</td>
</tr>
<tr>
<td>AE leading to study withdrawal, n (%)</td>
</tr>
<tr>
<td>SAEs, n (%)</td>
</tr>
</tbody>
</table>

Note: *Sorted by frequency in GB treatments.
Abbreviations: AE, adverse event; BID, twice daily; GB, glycopyrronium bromide; n, number of randomized patients; OD, once daily; SAEs, serious adverse events.
Table 4 Study Part 2: PK parameters of GB on Day 1 and Day 7

<table>
<thead>
<tr>
<th>Parameter</th>
<th>GB</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>12.5 µg BID</td>
</tr>
<tr>
<td></td>
<td>(n=36)</td>
</tr>
<tr>
<td>Plasma</td>
<td></td>
</tr>
<tr>
<td>Cmax (pg/mL)</td>
<td>24.3±13.3</td>
</tr>
<tr>
<td>τmax (h)</td>
<td>0.08 (0.08–0.25)</td>
</tr>
<tr>
<td>AUC0–12h (pg h/mL)</td>
<td>9.93±4.41</td>
</tr>
<tr>
<td>AUC0–t (pg h/mL)</td>
<td>38.4±27.6</td>
</tr>
<tr>
<td>AUC0–t (pg h/mL)</td>
<td>32.3±27.9</td>
</tr>
<tr>
<td>Urine</td>
<td></td>
</tr>
<tr>
<td>Aε0–12h (µg)</td>
<td>0.67±0.411</td>
</tr>
<tr>
<td>CLR (mL/min)</td>
<td>396±217</td>
</tr>
<tr>
<td>Day 7</td>
<td></td>
</tr>
<tr>
<td>Plasma</td>
<td></td>
</tr>
<tr>
<td>Cmax (pg/mL)</td>
<td>39.4±17.0</td>
</tr>
<tr>
<td>τmax (h)</td>
<td>0.08 (0.08–0.55)</td>
</tr>
<tr>
<td>Cmax (pg/mL)</td>
<td>BLOQ</td>
</tr>
<tr>
<td>AUC0–24h (pg h/mL)</td>
<td>14.6±5.59</td>
</tr>
<tr>
<td>AUC0–12h (pg h/mL)</td>
<td>87.0±41.7</td>
</tr>
<tr>
<td>AUC0–t (pg h/mL)</td>
<td>83.6±42.7</td>
</tr>
<tr>
<td>τmax (h)</td>
<td>4.90±3.13</td>
</tr>
<tr>
<td>Rε (x)</td>
<td>2.19 (1.09–8.27)</td>
</tr>
<tr>
<td>Urine</td>
<td></td>
</tr>
<tr>
<td>Aε0–12h (µg)</td>
<td>1.62±0.638</td>
</tr>
<tr>
<td>CLR (mL/min)</td>
<td>356±148</td>
</tr>
</tbody>
</table>

Notes: Values are arithmetic mean ± SD, except median (range) for τmax and Rε (calculated as AUC0–t). Day 7/Day 1). PK profiles were evaluated after morning administration.

Abbreviations: Ae, cumulative urinary excretion; AUC, area under the plasma concentration curve from administration to 30 min post-dose (0–30 min), from administration to last quantifiable concentration (0–t) and over the dosing interval (0–12 h); BID, twice daily; BLOQ, below limit of quantification; CLR, renal clearance; Cmax, maximum concentration; Cmin, minimum concentration; GB, glycopyrronium bromide; PK, pharmacokinetics; Rε, accumulation ratio; ss, steady state; τε, plasma elimination half-life; tmax, time of the maximum concentration.

doses of a novel extrafine GB formulation delivered by pMDI. This formulation was well tolerated in both parts of the study. Study Part 2 was a multiple-dose, BID-dosing, crossover study that provided important efficacy data; on Day 7, 25 µg BID was the lowest to meet the predefined threshold for clinical relevance for the primary endpoint (12 h trough FEV1) with a difference of ≥120 mL from placebo.

The dose response for GB in study Part 2 was also evaluated by considering the FEV1, AUC0–12h and peak FEV1 on Day 7. Consistent with the primary endpoint showing improvement of ≥120 mL compared to placebo for GB 25 and 50 µg BID, but not 12.5 µg BID, peak FEV1 showed a significantly greater improvement with GB 25 µg compared to 12.5 µg BID. The FEV1, AUC0–12h on Day 7 showed no significant difference between the GB doses, although numerically, the effect of GB 12.5 µg BID was the lowest. Overall, these data indicate that GB 25 and 50 µg BID caused greater lung function improvement than GB 12.5 µg BID, a finding supported by the Day 8 trough FEV1 analysis of GB compared to tiotropium. This suggests that GB 25 µg BID in this formulation may provide at least similar efficacy to tiotropium. This is consistent with data for the dry powder formulation of glycopyrronium, in which 50 µg OD was comparable to tiotropium in terms of lung function, dyspnea and health status. Overall, therefore, these results suggest that GB 25 µg BID is the optimal dose in patients with COPD.

The bronchodilator effects of inhaled glycopyrronium have been studied using both once and twice a day administration, with one study showing little difference between these regimens when the same daily dose was administered entirely in the morning or divided between morning and evening. The results reported here for twice a day administration are consistent with those for a porous particle pMDI formulation (in development for twice daily dosing), in which a single 28.8 µg dose resulted in differences from placebo of 158 mL in peak FEV1 and ~140 mL in FEV1, AUC0–12h. Given that we sought to evaluate the dose–response of GB, we enriched the population with individuals with
a greater response to muscarinic blockade, identified by an increase in FEV₁ ≥100 mL following inhalation of ipratropium at screening. Similar inclusion criteria have often been used in other early-phase clinical trials of novel LAMA formulations.14,15 This potentially limits the generalizability of the findings to a wider population, but this aspect can be addressed in later-phase clinical trials of longer duration with larger samples sizes. Furthermore, we used a tiotropium arm in order to help select GB doses that would be more likely to achieve at least comparable lung function improvements to those achieved with a commonly used LAMA.

The addition of a single dose of formoterol was associated with significant increases in peak FEV₁, FEV₁, AUC₀–₁₂h and 12 h trough FEV₁ for all treatments. Although this study only investigated bronchodilution, other studies have demonstrated the broad clinical benefits of combining long-acting bronchodilators, either in separate devices16,17 or as a fixed combination in the same inhaler,18-20 in terms of dyspnea,18,21,24 exercise endurance time22 and health status.19,23,28,29

Triple therapy with LABA, LAMA and ICS has shown additional advantages to patients in terms of bronchodilution, dyspnea and exacerbations,8-10,29-32 and is one of the most commonly prescribed maintenance treatments for COPD.33 A combination of BDP and FF is currently available in the same device as used for GB in this study (Foster®; Chiesi Farmaceutici S.p.A., Parma, Italy) and has a BID dosing regimen. A logical development is, therefore, the co-formulation of BDP/FF and GB in the same inhaler.9,10 Furthermore, the extrafine formulation has potential advantages over conventional large particle standard formulations in that it allows higher total lung deposition as well as for deeper and more uniform distribution within the airways.34

An unusual characteristic of the population recruited into both parts of this study is the high proportion of female patients. Most interventional clinical trials in COPD have recruited predominantly male populations – and as a consequence, much of the data available on the efficacy of bronchodilators is generated from men. Although a number of epidemiology studies have identified gender influences on the risk or progression of COPD,35-37 post hoc analyses of clinical trials suggest that gender does not seem to influence the response to bronchodilators.38,39

In the PK analyses, plasma concentration, systemic exposure and urinary excretion all increased with increasing dose – in most cases, the increase being proportional to GB dose. This is also consistent with the PK analysis of the dry powder glycopyrronium formulation, dosed OD.40 The main purpose of study Part 1 was to provide safety data in order to allow continuation to study Part 2 for efficacy analysis. Study Part 1 showed that a single dose (200 µg), greater than doses used in study Part 2, had a good overall safety and tolerability profile. Few AEs were considered related to treatment, and no SAEs were reported during GB treatment in either part of the study. There was no evidence of a dose–response in terms of the AE occurrence in either part of the study – although it should be noted that the study was not designed to evaluate such a dose–response (this would probably require much higher doses to be administered for a longer period). In addition, the exclusion criteria, typical of Phase II studies, meant that patients with clinically significant comorbidities were excluded from participation, and so, confirmation of the observed good overall safety and tolerability profile would need further studies in wider populations. However, in longer-term studies, inhaled GB (in a different formulation) has demonstrated an overall good safety profile.11,41,42

Although this study was relatively small and a short-term one, two studies have been conducted that provide long-term evidence on the efficacy and safety of GB 25 µg BID as part of a fixed triple combination of BDP/FF/GB.9,10 The study reported here was focused on lung function in order to identify the optimum dose for later-phase studies with larger sample sizes and longer duration that could also evaluate symptoms and exacerbations.9,10,43

In conclusion, this study provides initial evidence of the bronchodilator efficacy and safety and tolerability profile of this extrafine formulation of GB.

Acknowledgments
This study was funded by Chiesi Farmaceutici SpA. Writing support was provided by David Young of Young Medical Communications and Consulting Ltd. This support was funded by Chiesi Farmaceutici SpA.

Disclosure
DS has received sponsorship to attend international meetings, honoraria for lecturing or attending advisory boards and research grants from various pharmaceutical companies including Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Genentech, GlaxoSmithKline, Glenmark, Johnson and Johnson, Merck, NAPP, Novartis, Pfizer, Skypharma, Takeda, Teva, Theraveance and Verona. MS, SC, SV, FM, AM and DA are employees of Chiesi Farmaceutici SpA, the study sponsor. The authors report no other conflicts of interest in this work.
References


**Supplementary materials**

**Inclusion criteria**

Subjects had to meet all of the following inclusion criteria (applicable for study Parts 1 and 2):

1. Male and female subjects, aged 40–75 years.
2. Written informed consent obtained before the first study-related activity.
3. Diagnosis of moderate–severe COPD, according to the Global Initiative for Chronic Obstructive Lung Disease guidelines (2009).
4. Able to understand the study procedures, the risks involved and the ability to be trained to use the devices correctly.
5. Body mass index between 18 and 35 kg/m².
6. Current or ex-smokers with a smoking history of ≥10 pack-years (eg, ≥20 cigarettes per day for 10 years and 40 cigarettes per day for 5 years).
7. Vital signs within the following ranges:
   - 90 mmHg ≤ systolic blood pressure ≤ 160 mmHg.
   - 50 mmHg ≤ diastolic blood pressure ≤ 90 mmHg.
   - 50 beats per min ≤ heart rate ≤ 100 beats per min.
8. Twelve-lead electrocardiogram (ECG) with computerized protocol interpretation considered as normal: 120 ms ≤ PR ≤ 200 ms; QRS ≤ 120 ms; QTcF ≤ 450 ms. Minor deviations were acceptable, provided that they were not judged clinically significant by the cardiologist.
9. Post-bronchodilator forced expiratory volume in 1 second ($FEV_1$) between 40% and 80% predicted values ($40\% \leq FEV_1 \leq 80\%$), documented at the screening visit.
10. Post-bronchodilator FEV₁/forced vital capacity: ≤ 70 (absolute value) documented at the screening visit.
11. Airway reversibility of at least 100 mL within 30–45 min after inhalation of ipratropium 80 µg (for study Part 2: historical reversibility was acceptable for subjects who performed study Part 1). If the reversibility criteria were not met and if the investigator deemed it appropriate, the testing could be repeated once. This requirement had to be met after retesting during the run-in period at least 24 h prior to randomization.

**Exclusion criteria**

Subjects meeting at least one of the following criteria could not be enrolled (applicable for study Parts 1 and 2):

1. History of chronic or seasonal allergy.
2. Blood eosinophil count above 0.6×10⁹/L.
3. Clinically relevant findings on physical examination, laboratory or ECG parameters at screening. (Note that one patient had a prolonged QTc at screening and was allowed to enter the study by the investigator, who considered this to be not clinically relevant. The subject was later withdrawn from the study, as the study was designed to exercise caution in subjects who may be predisposed to an increased risk of cardiovascular events.)
4. Occurrence of one of the following 24 h Holter ECG abnormalities at screening:
   - More than 200 ventricular ectopics in 24 h;
   - Ventricular tachycardia;
   - Second-degree heart block;
   - Sustained cardiac arrhythmias (atrial fibrillation, supraventricular tachycardia, complete heart block);
   - Any symptomatic arrhythmia (except isolated extrasystoles);
   - Sinus pauses ≥ 2.5 s.
5. Significant disease not related to COPD (eg, myocardial infarction, stroke within the preceding 6 months).
6. Respiratory tract infection (including upper tract) 4 weeks prior to the screening visit, requiring change of treatment.
7. Subjects requiring oxygen therapy on a daily basis for chronic hypoxemia.
8. Subjects who had been hospitalized in the 6 weeks prior to the screening visit.
9. Having received an investigational product within the last 8 weeks before the screening visit.
10. Inability to comply with the study procedures or with the study treatment intake, including inability to be trained with the Vitalograph® Aerosol Inhalation Monitor.
11. History of cystic fibrosis, bronchiectasis, alpha-1 antitrypsin deficiency or any other significant lung disease that was considered to be clinically significant by the investigator.
12. Intolerance/hypersensitivity or any contraindication (eg, history of glaucoma) to treatment with an M3 antagonist or any of the excipients contained in the formulations used in the study.
13. History of alcohol or substance abuse that, in the opinion of the investigator, could be of clinical significance.
14. Subjects who had undergone major surgery in the 12 weeks before the screening visit.
15. Subjects treated with oral (slow-release included) or parenteral steroids 8 weeks prior to the screening visit.
16. Subjects treated with oral β2-adrenergics, antihistamines or theophyllines 1 month prior to the screening visit or enzyme-inducing or -inhibiting drugs 2 months before the first administration.

17. Subjects treated with tiotropium in the 10 days prior to the screening visit.

18. (a) Pregnant or lactating women (pregnancy defined as the state of a female after conception and until the termination of the gestation, confirmed by a positive serum human chorionic gonadotropin laboratory test [≥5 mIU/mL]). Serum pregnancy test was to be done at screening for verification.

(b) Women of childbearing potential (ie, all women physiologically capable of becoming pregnant), including women whose career, lifestyle or sexual orientation precluded intercourse with a male partner, unless they were postmenopausal (defined as 12 months of natural [spontaneous] amenorrhea) or were using an acceptable method of contraception.

(c) Male subjects had to be sterile or they or their partner had to be willing to use an approved method of contraception from the time of dose administration until 30 days after the last dose of study medication. Subjects were not allowed to donate sperm for 30 days after the last dose of study drug. A reliable method of contraception for male and female subjects (or their partner) could be one or more of the following ones:

- Surgical sterilization (ie, bilateral tubal ligation or hysterectomy for females; vasectomy for males);
- Hormonal contraception (implantable, patch, or oral);
- Double-barrier methods (any double combination of intrauterine device, male or female condom, diaphragm, sponge, cervical cap, condom or spermicide).

Periodic abstinence (ie, calendar, ovulation, symptothermal, or postovulation methods) and withdrawal were not acceptable methods of contraception. Reliable contraception was to be maintained throughout the study.

Figure S1 Study Part 2: Difference in 12 h trough FEV1 between Day 7 and Day 8, following administration of formoterol.

Notes: *P<0.001 versus Day 7. Data plotted are mean and 95% CI.

Abbreviations: BID, twice daily; CI, confidence interval; FEV1, forced expiratory volume in 1 second; GB, glycopyrronium bromide; n, number of randomized patients.